BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37419930)

  • 1. A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes.
    Yang W; Pang Y; Wang X; Lai Z; Lu Y; Zheng S; Wang W
    Cell Death Dis; 2023 Jul; 14(7):406. PubMed ID: 37419930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CTLA-4 blocking strategy based on Nanoboby in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects.
    Wang W; Wang X; Yang W; Zhong K; He N; Li X; Pang Y; Lu Z; Liu A; Lu X
    BMC Cancer; 2021 Sep; 21(1):1029. PubMed ID: 34525966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.
    Shi W; Yang X; Xie S; Zhong D; Lin X; Ding Z; Duan S; Mo F; Liu A; Yin S; Jiang X; Xu ZPG; Lu X
    Cancer Lett; 2021 Dec; 522():184-197. PubMed ID: 34562519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel doxorubicin/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy.
    Yang W; Sun Q; Zhang X; Zheng L; Yang X; He N; Pang Y; Wang X; Lai Z; Zheng W; Zheng S; Wang W
    Cell Death Dis; 2024 Jun; 15(6):386. PubMed ID: 38824143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.
    McCoy KD; Hermans IF; Fraser JH; Le Gros G; Ronchese F
    J Exp Med; 1999 Apr; 189(7):1157-62. PubMed ID: 10190907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
    Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
    J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Nanobody Against Cytotoxic T-Lymphocyte Associated Antigen-4 Increases the Anti-Tumor Effects of Specific CD8
    Tang Z; Mo F; Liu A; Duan S; Yang X; Liang L; Hou X; Yin S; Jiang X; Vasylieva N; Dong J; Barnych B; Hammock BD; Lu X
    J Biomed Nanotechnol; 2019 Nov; 15(11):2229-2239. PubMed ID: 31847937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; OnoƩ K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
    Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine.
    Esmaily M; Masjedi A; Hallaj S; Nabi Afjadi M; Malakotikhah F; Ghani S; Ahmadi A; Sojoodi M; Hassannia H; Atyabi F; Namdar A; Azizi G; Ghalamfarsa G; Jadidi-Niaragh F
    J Control Release; 2020 Oct; 326():63-74. PubMed ID: 32580042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor.
    Sun S; Ding Z; Gao L; Hammock BD; Huang X; Xu ZP; Wang X; Cheng Q; Mo F; Shi W; Xie S; Liu A; Li H; Yang X; Lu X
    Theranostics; 2023; 13(14):5099-5113. PubMed ID: 37771772
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.
    Pruitt SK; Boczkowski D; de Rosa N; Haley NR; Morse MA; Tyler DS; Dannull J; Nair S
    Eur J Immunol; 2011 Dec; 41(12):3553-63. PubMed ID: 22028176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
    Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
    Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
    Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
    Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.